1. Genetics and treatment of gastrointestinal stromal tumors with immune checkpoint inhibitors: what do we know?
- Author
-
Maria Abbondanza Pantaleo, Milena Urbini, Margherita Nannini, Valentina Indio, Annalisa Astolfi, Indio, Valentina, Astolfi, Annalisa, Urbini, Milena, Nannini, Margherita, and Pantaleo, Maria A
- Subjects
Stromal cell ,tumor infiltrating lymphocytes (TILs) ,Gastrointestinal Stromal Tumors ,Pyridines ,medicine.medical_treatment ,Immune checkpoint inhibitors ,PD-L1 expression ,CD8+ T cells ,M2 macrophage ,NO ,CD4+ T cell ,CD4+ T cells ,IFN-γ signaling pathway ,M2 macrophages ,checkpoint inhibitors ,gastrointestinal stromal tumors (GISTs) ,immunotherapy ,hemic and lymphatic diseases ,Sunitinib ,Genetics ,Humans ,Medicine ,Cytotoxic T cell ,Gastrointestinal stromal tumors (GISTs) ,neoplasms ,Immune Checkpoint Inhibitors ,Protein Kinase Inhibitors ,Pharmacology ,business.industry ,Phenylurea Compounds ,Immunotherapy ,biochemical phenomena, metabolism, and nutrition ,Prognosis ,medicine.disease ,digestive system diseases ,checkpoint inhibitor ,Disease Progression ,Imatinib Mesylate ,Cancer research ,Molecular Medicine ,Pd l1 expression ,CD8+ T cell ,business - Abstract
tumor-infiltrating immune cells are present in GIST and seem to be associated with disease outcomes and also with increasing the activity of imatinib”
- Published
- 2020
- Full Text
- View/download PDF